Athersys Company Profile (NASDAQ:ATHX)

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATHX
  • CUSIP: N/A
  • Web: www.athersys.com
Capitalization:
  • Market Cap: $209.6 million
  • Outstanding Shares: 113,911,000
Average Prices:
  • 50 Day Moving Avg: $2.19
  • 200 Day Moving Avg: $1.70
  • 52 Week Range: $1.02 - $2.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.74
  • P/E Growth: -0.34
Sales & Book Value:
  • Annual Revenue: $3.43 million
  • Price / Sales: 66.09
  • Book Value: $0.23 per share
  • Price / Book: 8.65
Profitability:
  • EBITDA: ($27,300,000.00)
  • Net Margins: -729.07%
  • Return on Equity: -121.47%
  • Return on Assets: -88.83%
Debt:
  • Current Ratio: 4.50%
  • Quick Ratio: 4.50%
Misc:
  • Average Volume: 1.17 million shs.
  • Beta: -0.14
  • Short Ratio: 11.19
 

Frequently Asked Questions for Athersys (NASDAQ:ATHX)

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The company earned $0.67 million during the quarter, compared to the consensus estimate of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The firm's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.08) EPS. View Athersys' Earnings History.

When will Athersys make its next earnings announcement?

Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Athersys.

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

3 brokerages have issued 12 month target prices for Athersys' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Athersys' share price to reach $9.50 in the next twelve months. View Analyst Ratings for Athersys.

What are analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • 1. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (10/10/2017)
  • 2. Maxim Group analysts commented, "A negative blogger blasted Athersys Multistem with Zombie" like properties as a therapeutic that just won’t die. The article (in our opinion) picks and chooses elements of the Athersys story which when taken out of context paint a confusing picture." (10/5/2017)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:

  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
  • William Lehmann Jr, President, Chief Operating Officer
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
  • Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
  • Laura K. Campbell CPA, Vice President - Finance
  • Lee E. Babiss Ph.D., Lead Independent Director
  • Ismail Kola, Independent Director
  • Lorin Jeffry Randall, Independent Director
  • Jack L. Wyszomierski, Independent Director

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of Athersys stock can currently be purchased for approximately $1.99.


MarketBeat Community Rating for Athersys (NASDAQ ATHX)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  222
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Athersys (NASDAQ:ATHX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (377.39% upside)
Consensus Price Target History for Athersys (NASDAQ:ATHX)
Price Target History for Athersys (NASDAQ:ATHX)
Analysts' Ratings History for Athersys (NASDAQ:ATHX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017Maxim GroupSet Price TargetBuy$12.00N/AView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Athersys (NASDAQ:ATHX)
Earnings by Quarter for Athersys (NASDAQ:ATHX)
Earnings History by Quarter for Athersys (NASDAQ ATHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.06)$0.96 million$0.67 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.07)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Athersys (NASDAQ:ATHX)
2017 EPS Consensus Estimate: ($0.27)
2018 EPS Consensus Estimate: ($0.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.07)($0.07)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.07)($0.06)($0.07)
Q4 20172($0.08)($0.06)($0.07)
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 19.11%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2017William Lehmann JrInsiderSell15,000$2.38$35,700.00View SEC Filing  
9/18/2017John J HarringtonEVPSell15,000$2.17$32,550.00View SEC Filing  
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
Source:
DateHeadline
seekingalpha.com logoBears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future
seekingalpha.com - October 14 at 2:43 AM
finance.yahoo.com logoFeatured Company News - Athersys Signs Agreement with Nikon CeLL Innovation for Commercial Manufacturing of MultiStem in Japan
finance.yahoo.com - October 13 at 4:39 PM
seekingalpha.com logoAthersys Partners Up: Can Nikon CeLL Get MultiStem On Track? - Seeking Alpha
seekingalpha.com - October 13 at 2:58 AM
nasdaq.com logoAthersys (ATHX) in Focus: Stock Moves 7.2% Higher - Nasdaq
www.nasdaq.com - October 13 at 2:58 AM
finance.yahoo.com logoAthersys (ATHX) in Focus: Stock Moves 7.2% Higher
finance.yahoo.com - October 12 at 4:57 PM
baystreet.ca logoAthersys Hikes on MultiStem Hookup with Japanese Firm
www.baystreet.ca - October 11 at 5:41 PM
streetinsider.com logoAthersys (ATHX) Reports Collaboration Agreement with Nikon Cell Innovation Co. on MultiStem Commercial Manufacturing in Japan
www.streetinsider.com - October 11 at 5:41 PM
finance.yahoo.com logoAthersys and Nikon CeLL Innovation to Collaborate on MultiStem® Commercial Manufacturing in Japan
finance.yahoo.com - October 11 at 5:41 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 5:46 PM
nasdaq.com logoMid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher
www.nasdaq.com - October 10 at 5:25 PM
feeds.benzinga.com logoAthersys to Host Third Quarter Financial Results Call
feeds.benzinga.com - October 9 at 11:35 AM
americanbankingnews.com logoAthersys (ATHX) & Its Rivals Head to Head Survey
www.americanbankingnews.com - October 8 at 9:00 AM
americanbankingnews.com logoWilliam Blair Weighs in on Athersys, Inc.'s Q1 2018 Earnings (ATHX)
www.americanbankingnews.com - October 6 at 11:04 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: October 6, 2017
seekingalpha.com - October 6 at 9:07 AM
americanbankingnews.com logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - October 5 at 9:30 PM
americanbankingnews.com logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - October 5 at 9:30 PM
streetinsider.com logoAthersys (ATHX) Announces RMAT Designation From FDA - StreetInsider.com
www.streetinsider.com - October 5 at 7:01 PM
seekingalpha.com logoAthersys: Cash Concerns Cast A Long Shadow - Seeking Alpha
seekingalpha.com - September 28 at 4:33 PM
americanbankingnews.com logoInsider Selling: Athersys, Inc. (ATHX) EVP Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 19 at 8:32 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Insider William Lehmann, Jr. Sells 15,000 Shares
www.americanbankingnews.com - September 19 at 8:32 PM
seekingalpha.com logoRegulatory Alignment Reinforces Bullish Case For Athersys - Seeking Alpha
seekingalpha.com - September 19 at 4:09 PM
seekingalpha.com logoAthersys Multistem Partner Healios KK Delays Implementation Of Critical Phase III TREASURE Trial - Seeking Alpha
seekingalpha.com - September 11 at 4:12 PM
nasdaq.com logoAthersys (ATHX) in Focus: Stock Moves 10.22% Higher - Nasdaq
www.nasdaq.com - September 8 at 2:12 AM
americanbankingnews.com logoAthersys, Inc. (ATHX) Given Buy Rating at Maxim Group
www.americanbankingnews.com - September 4 at 2:32 PM
americanbankingnews.com logoAthersys, Inc. to Post Q4 2017 Earnings of ($0.08) Per Share, William Blair Forecasts (NASDAQ:ATHX)
www.americanbankingnews.com - August 14 at 6:42 AM
americanbankingnews.com logoAthersys, Inc. (ATHX) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - August 10 at 3:42 PM
finance.yahoo.com logoEdited Transcript of ATHX earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 3:35 PM
globenewswire.com logoAthersys Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 4:20 PM
finance.yahoo.com logoFeatured Company News – Athersys Reported Alignment of Key Regulators for Pivotal Registration Study in Ischemic Stroke
finance.yahoo.com - August 9 at 4:20 PM
finance.yahoo.com logoInvestor Network: Athersys, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 4:19 PM
finance.yahoo.com logoAthersys Reports Second Quarter 2017 Results
finance.yahoo.com - August 9 at 4:19 PM
finance.yahoo.com logoAthersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke
finance.yahoo.com - August 7 at 4:56 PM
americanbankingnews.com logoMaxim Group Analysts Give Athersys, Inc. (ATHX) a $9.00 Price Target
www.americanbankingnews.com - August 7 at 1:08 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) to Release Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:18 AM
seekingalpha.com logoAthersys's Cardiovascular Health Program Is Ambitious and Well-Calculated - Seeking Alpha
seekingalpha.com - July 28 at 10:22 PM
globenewswire.com logoAthersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release)
globenewswire.com - July 10 at 4:10 PM
finance.yahoo.com logoAthersys to Host Second Quarter Financial Results Call
finance.yahoo.com - July 10 at 4:10 PM
americanbankingnews.com logo Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 10 at 2:30 PM
finance.yahoo.com logoETFs with exposure to Athersys, Inc. : July 7, 2017
finance.yahoo.com - July 8 at 7:02 AM
seekingalpha.com logoAthersys And Aurinia Target Human And Animal Health - Seeking Alpha
seekingalpha.com - June 27 at 3:50 PM
nasdaq.com logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - June 9 at 2:28 AM
seekingalpha.com logoUpcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha
seekingalpha.com - May 31 at 3:41 PM
seekingalpha.com logoAthersys Poised For Lucrative Stem Cell Stroke Partnership This Year
seekingalpha.com - May 16 at 12:30 PM
seekingalpha.com logoAthersys beats by $0.01, beats on revenue
seekingalpha.com - May 11 at 9:11 PM
seekingalpha.com logoAthersys: Initiating Coverage With Buy Rating And Price Target Of $8
seekingalpha.com - April 19 at 4:00 PM
fool.com logoHere's What Might Be Pushing Up Shares of Athersys, Inc. Today
www.fool.com - March 31 at 3:49 PM
investopedia.com logoAthersys (ATHX) Stock Rallies as William Blair Initiates Coverage
www.investopedia.com - March 29 at 8:53 PM
streetinsider.com logoAthersys (ATHX) Says Two Publications Highlight MultiStem for Treating Ischemic Stroke
www.streetinsider.com - March 20 at 8:53 AM
us.rd.yahoo.com logoTwo New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke
us.rd.yahoo.com - March 20 at 8:53 AM
us.rd.yahoo.com logo6:31 am Athersys announces that clinical investigators have published results from Athersys' Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients in the peer-reviewed journal The Lancet Neurology
us.rd.yahoo.com - March 20 at 8:53 AM

Social

Chart

Athersys (ATHX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.